This inventor holds 1 USPTO granted patent. Top assignee: Astellas Pharma Gmbh. Active years: 2013.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2013
Title: Fumie Sato: Innovator in Quinolone Derivatives
Introduction
Fumie Sato is a prominent inventor based in Tokyo, Japan. She has made significant contributions to the field of medicinal chemistry, particularly in the development of NAD(P)H oxidase inhibitors. Her innovative work has the potential to impact the treatment of various metabolic disorders.
Latest Patents
Fumie Sato holds a patent for a quinolone derivative. This compound exhibits excellent NAD(P)H oxidase inhibitory activity, which is crucial for reducing the production of reactive oxygen species. The invention aims to provide a therapeutic agent for preventing and treating conditions such as diabetes, impaired glucose tolerance, hyperlipidemia, and diabetic complications. She has 1 patent to her name.
Career Highlights
Fumie Sato is currently associated with Astellas Pharma GmbH, where she continues her research and development efforts. Her work is characterized by a strong focus on innovative solutions to complex health issues.
Collaborations
Fumie collaborates with notable colleagues, including Kenichi Onda and Kenichiro Imamura. Their combined expertise enhances the research and development initiatives at Astellas Pharma.
Conclusion
Fumie Sato's contributions to the field of medicinal chemistry, particularly through her patent on quinolone derivatives, highlight her role as an influential inventor. Her work promises to advance the treatment of significant health challenges.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile